ARDX241115C3000
- 0.00
- 0.000.00%
Ardelyx Newsroom
Ardelyx Insider Bought Shares Worth $996,598, According to a Recent SEC Filing
Ardelyx Down as H.C. Wainwright Downgrades Rating on Anticipated Xphozah Sales Drop
Improved Revenues Required Before Ardelyx, Inc. (NASDAQ:ARDX) Shares Find Their Feet
H.C. Wainwright Downgrades Ardelyx(ARDX.US) to Hold Rating, Cuts Target Price to $5.5
Express News | Ardelyx Inc : H.c. Wainwright Cuts to Neutral,
Express News | Ardelyx Responds to District Court Decision Granting Motion to Dismiss
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
Ardelyx Is Maintained at Buy by Citigroup
Ardelyx's Strong Sales and Strategic Positioning Reinforce Buy Rating Amid Reimbursement Uncertainties
Ardelyx Price Target Lowered to $10 From $12 at Citi
A Quick Look at Today's Ratings for Ardelyx(ARDX.US), With a Forecast Between $7 to $13.5
Ardelyx Analyst Ratings
Express News | Ardelyx Inc : Leerink Partners Raises Target Price to $11 From $10
Piper Sandler Maintains Ardelyx(ARDX.US) With Hold Rating, Maintains Target Price $7
Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript Summary
Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript
TD Cowen Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $12
Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics
Ardelyx Beats Q3 Sales Estimates, Shares Climb
12 Health Care Stocks Moving In Thursday's After-Market Session